Trial Profile

A randomized, double-blind trial Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clobetasol (Primary)
Indications Ocular inflammation; Ocular pain; Postoperative inflammation; Postoperative pain
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms CPN-303
Sponsors Formosa Pharmaceuticals

Most Recent Events

10 Feb 2025 New trial record
04 Nov 2024 Results published in the Formosa Pharmaceuticals Media Release
04 Nov 2024 According to Formosa Pharmaceuticals Media Release, Primary endpoint (complete and sustained resolution of ocular inflammation and pain after cataract surgery) has been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com